(Q51926925)

17 April 2018

title

Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes. (English)

1 reference

17 April 2018

author name string

Katherine A Rittenbach

1

1 reference

17 April 2018

Andrew Holt

2

1 reference

17 April 2018

Lei Ling

3

1 reference

17 April 2018

Jackie Shan

4

1 reference

17 April 2018

Glen B Baker

5

1 reference

17 April 2018

publication date

8 December 2006

1 reference

17 April 2018

Cellular and Molecular Neurobiology

published in

1 reference

17 April 2018

volume

27

1 reference

17 April 2018

issue

2

1 reference

17 April 2018

page(s)

179-190

1 reference

17 April 2018

https://scigraph.springernature.com/pub.10.1007/s10571-006-9085-1

exact match

0 references

cites work

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10571-006-9085-1

Pharmacologic treatment of Alzheimer's disease: an update

21 January 2018

1 reference

12 December 2020

Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments.

1 reference

12 December 2020

Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I.

1 reference

12 December 2020

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

1 reference

12 December 2020

Selegiline for Alzheimer's disease

1 reference

12 December 2020

Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion.

1 reference

12 December 2020

Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes

1 reference

12 December 2020

Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems

1 reference

12 December 2020

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

1 reference

12 December 2020

L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.

1 reference

12 December 2020

Newer antidepressants and the cytochrome P450 system

1 reference

12 December 2020

A rapid, sensitive electron-capture gas chromatographic procedure for analysis of metabolites of N-methyl,N-propargylphenylethylamine, a potential neuroprotective agent

1 reference

12 December 2020

1 reference

12 December 2020

Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage.

1 reference

12 December 2020

Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6.

1 reference

12 December 2020

Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.

1 reference

12 December 2020

Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline

1 reference

12 December 2020

Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and N-methyl,N-propargylphenylethylamine

1 reference

12 December 2020

Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs

1 reference

12 December 2020

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

1 reference

12 December 2020

Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency.

1 reference

12 December 2020

Neuroprotection in Parkinson's disease: clinical trials

1 reference

12 December 2020

(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.

1 reference

12 December 2020

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

1 reference

12 December 2020

CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes

1 reference

12 December 2020

Selegiline's neuroprotective capacity revisited

1 reference

12 December 2020

Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling.

1 reference

12 December 2020

CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

1 reference

12 December 2020

R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium.

1 reference

12 December 2020

Selegiline can mediate neuronal rescue rather than neuronal protection

1 reference

12 December 2020

Neuroprotective strategies in Parkinson's disease : an update on progress

1 reference

12 December 2020

Neuroprotective actions of selegiline

1 reference

12 December 2020

A rapid electron-capture gas chromatographic procedure for the analysis of p-hydroxymephenytoin

1 reference

12 December 2020

10.1007/S10571-006-9085-1

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018